WHO International Standard
1st International Standard for Cetuximab
NIBSC code: 21/170
Instructions for use
(Version 1.0, Dated 07/12/2022)

1. INTENDED USE
The World Health Organisation (WHO) Expert Committee on Biological Standardisation (ECBS) recognised the need for a reference standard to evaluate the performance of bioassays used to assess the biological activities of cetuximab. This international standard preparation is intended to support the characterisation, calibration and validation of assays used to assess the biological activities of cetuximab and support the establishment and calibration of in house reference standards.

It should be noted that the unitage assigned to this standard is not intended to define specific activity for regulatory purposes neither to describe labelling or dosage of cetuximab products. Further, the properties and characteristics of the material used to make this preparation are not intended to serve any regulatory role in defining biosimilarity, and should not be extrapolated, calculated, or inferred as serving this purpose in anyway whatsoever. The cetuximab preparation 21/170 has been evaluated in an international multi-centre collaborative study (described in section 3).

2. CAUTION
This preparation is not for administration to humans or animals in the human food chain.

The preparation contains material of human origin, and either the final product or the source materials, from which it is derived, have been tested and found negative for HBsAg, anti-HIV and HCV RNA.

3. UNITAGE
The preparation has been assigned the following arbitrary unitage: 1,000 International Units (IU) of Inhibition of Proliferation (IOP) activity per ampoule
1,000 IU of Antibody-dependent cell-mediated cytotoxic (ADCC) activity per ampoule
1,000 IU of Epidermal growth factor receptor (EGFR) binding activity per ampoule
1,000 IU of Fraction crystallizable gamma receptor III-A high affinity polymorphic allotype V158 (FcyRIIIa(V158)) binding activity per ampoule
1,000 IU of Fraction crystallizable gamma receptor I (FcyRI) binding activity per ampoule

The bioactivity of the preparation was established using IOP (including inhibition of EGFR signalling), EGFR binding, ADCC, and FcγR binding assays, using both, cell-based and non-cell-based assay platforms. EGFR expressing cell lines or EGFR captured on a solid matrix were used as targets, and primary human PBMC or Natural killer (NK) cells, NK cell lines and FcγRIIIa transfected cells were used as effectors in ADCC. FcγR expressing cells and soluble or FcγR captured on a solid matrix were used in FcγR binding assays. The study included data from 22 laboratories from 12 different countries: 15 laboratories for IOP, 15 laboratories for EGFR binding assays, 6 laboratories for ADCC (7 assays), and 2 laboratories performing 8 FcγR binding assays and 1 assay for Clq binding. Participants evaluated the preparation using their qualified in house bioassays. Data was returned for viability, cytotoxicity, receptor dimerization and phosphorylation, and/or reporter gene and binding assay results.

4. CONTENTS
Country of origin of biological material: United Kingdom.
Each ampoule is the lyophilised residue of a 1 mL solution containing approximately 100 μg of cetuximab protein, 145.1 mM sodium chloride, 7 mM sodium phosphate dibasic heptahydrate, 2.6 mM sodium phosphate, 0.05% (v/v) clinical grade human serum albumin pH 7.0-7.4. Note that the quantity in mass of cetuximab is given as approximate for guidance, however, it is not a formally assigned content and should not be used to calculate or infer a specific biological activity.

5. STORAGE
Unopened ampoules should be stored at -20 ºC. Please note because of the inherent stability of lyophilized material, NIBSC may ship these materials at ambient temperature.

6. DIRECTIONS FOR OPENING
DIN ampoules have an ‘easy-open’ coloured stress point, where the narrow ampoule stem joins the wider ampoule body. Various types of ampoule breaker are available commercially. To open the ampoule, tap the ampoule gently to collect material at the bottom (labelled) end and follow manufactures instructions provided with the ampoule breaker.

7. USE OF MATERIAL
No attempt should be made to weigh out any portion of the freeze-dried material prior to reconstitution

Dissolve the total contents of the ampoule in 1.0 mL of sterile distilled water. This solution will contain cetuximab protein at a concentration which provides 1,000 IU/mL of IOP activity, 1,000 IU/mL of EGFR-binding activity, 1,000 IU/mL ADCC activity, 1,000 IU of FcγRIIIa(V158) binding activity and 1,000 IU of FcγRI binding activity.

8. STABILITY
Reference materials are held at NIBSC within assured, temperature-controlled storage facilities. Reference Materials should be stored on receipt as indicated on the label.

NIBSC follows the policy of WHO with respect to its reference materials. Thus, no expiring date is assigned to international reference materials. Accelerated degradation studies have indicated that this material is suitably stable when stored at the recommended -20 ºC or below, for the assigned values. Once reconstituted, diluted or aliquoted, users should determine the stability of the material according to their own method of preparation, storage and use. Users who have data supporting any deterioration in the characteristics of any reference preparation are encouraged to contact NIBSC.

NIBSC follows the policy of WHO with respect to its reference materials.

9. REFERENCES
This standard was produced under WHO guidelines cited in the WHO Technical Reports Series, No. 932, 2006, Annex 2.

Report on a collaborative study for proposed candidate 1st International standard for the cetuximab will be made available in: https://www.who.int/publications/m/item/who-bs-2022.2429

10. ACKNOWLEDGEMENTS
We are thankful to all the participants of the collaborative study for their contribution in evaluating the candidate preparation.
11. FURTHER INFORMATION
Further information can be obtained as follows;
This material: enquiries@nibsc.org
WHO Biological Standards:
http://www.who.int/biologicals/en/
JCTLM Higher order reference materials:
http://www.bipm.org/en/committees/jc/jctlm/
Derivation of International Units:
http://www.nibsc.org/standardisation/international_standards.aspx
Ordering standards from NIBSC:
http://www.nibsc.org/products/ordering.aspx
NIBSC Terms & Conditions:
http://www.nibsc.org/terms_and_conditions.aspx

12. CUSTOMER FEEDBACK
Customers are encouraged to provide feedback on the suitability or use of the material provided or other aspects of our service. Please send any comments to enquiries@nibsc.org

13. CITATION
In all publications, including data sheets, in which this material is referenced, it is important that the preparation’s title, its status, the NIBSC code number, and the name and address of NIBSC are cited and cited correctly.

14. MATERIAL SAFETY SHEET
Classification in accordance with Directive 2000/54/EC, Regulation (EC) No 1272/2008: Not applicable or not classified

<table>
<thead>
<tr>
<th>Physical and Chemical properties</th>
</tr>
</thead>
<tbody>
<tr>
<td>Physical appearance: Lyophilisate</td>
</tr>
<tr>
<td>Corrosive: No</td>
</tr>
<tr>
<td>Stable: Yes</td>
</tr>
<tr>
<td>Oxidising: No</td>
</tr>
<tr>
<td>Hygroscopic: No</td>
</tr>
<tr>
<td>Irritant: Unknown</td>
</tr>
<tr>
<td>Flammable: No</td>
</tr>
<tr>
<td>Handling: See caution, Section 2</td>
</tr>
</tbody>
</table>

Other (specify): The preparation contains material of human origin. Either the final product or the source materials, from which it is derived, have been tested and found negative for HBsAg, anti-HIV and HCV RNA.

Toxicological properties

- Effects of inhalation: Not established, avoid inhalation
- Effects of ingestion: Not established, avoid ingestion
- Effects of skin absorption: Not established, avoid contact with skin

Suggested First Aid

- Inhalation: Seek medical advice
- Ingestion: Seek medical advice
- Contact with eyes: Wash with copious amounts of water. Seek medical advice
- Contact with skin: Wash thoroughly with water.

15. LIABILITY AND LOSS
In the event that this document is translated into another language, the English language version shall prevail in the event of any inconsistencies between the documents. Unless expressly stated otherwise by NIBSC, NIBSC’s Standard Terms and Conditions for the Supply of Materials (available at http://www.nibsc.org/About_Us/Terms_and_Conditions.aspx or upon request by the Recipient) ("Conditions") apply to the exclusion of all other terms and are hereby incorporated into this document by reference. The Recipient’s attention is drawn in particular to the provisions of clause 11 of the Conditions.

16. INFORMATION FOR CUSTOMS USE ONLY

| Country of origin for customs purposes*: United Kingdom |
| Toxicity Statement: Toxicity not assessed |
| Veterinary certificate or other statement if applicable. |
| Attached: No |

17. CERTIFICATE OF ANALYSIS
NIBSC does not provide a Certificate of Analysis for WHO Biological Reference Materials because they are internationally recognised primary reference materials fully described in the instructions for use. The reference materials are established according to the WHO Recommendations for the preparation, characterization and establishment of international and other biological reference standards
http://www.who.int/bloodproducts/publications/TRS932Annex2_Inter_biolefstandardsrev2004.pdf (revised 2004). They are officially endorsed by the WHO Expert Committee on Biological Standardization (ECBS) based on the report of the international collaborative study which established their suitability for the intended use.